Skip to main content

CARLSMED, INC.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

CARL$14.52-5.2%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

(in thousands, except share and per share amounts)

Three Months EndedJune 30,Six Months EndedJune 30,
2026202520262025
Revenue$18,940$12,083$35,056$22,272
Cost of sales4,3983,2148,0895,767
Gross profit14,5428,86926,96716,505
Operating expenses:
Research and development6,0404,16011,2187,310
Sales and marketing11,9207,86922,21714,608
General and administrative7,6183,34213,8446,808
Total operating expenses25,57815,37147,27928,726
Loss from operations(11,036)(6,502)(20,312)(12,221)
Other income (expense):
Interest expense(313)(363)(624)(720)
Interest income8393361,730716
Change in fair value of warrant liabilities—(237)—(270)
Total other income (expense), net526(264)1,106(274)
Net loss(10,510)(6,766)(19,206)(12,495)
Deemed dividend to preferred stockholders———(584)
Net loss attributable to common stockholders$(10,510)$(6,766)$(19,206)$(13,079)
Net loss$(10,510)$(6,766)$(19,206)$(12,495)
Other comprehensive loss:
Unrealized loss on available-for-sale debt securities(17)—(17)—
Total other comprehensive loss(17)—(17)—
Total comprehensive loss$(10,527)$(6,766)$(19,223)$(12,495)
Net loss per share attributable to common stockholders, basic and diluted$(0.39)$(1.47)$(0.71)$(2.94)
Weighted-average number of common shares used to compute basic and diluted net loss per share27,190,7654,589,71727,003,8684,445,384
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.